Welcome to our dedicated page for Cryoport SEC filings (Ticker: CYRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cryoport, Inc. filings document the regulatory record for a Nasdaq-listed Nevada corporation providing temperature-controlled supply chain solutions to life sciences customers. Recent Form 8-K reports furnish quarterly and annual results releases, while definitive proxy materials describe governance matters, stockholder voting items and business updates tied to Life Sciences Services and Life Sciences Products.
The filing record also identifies Cryoport's registered common stock and recurring disclosure subjects such as operating performance, commercial and clinical cell and gene therapy support, biostorage and bioservices activity, cryogenic systems demand, executive and board governance, and stockholder meeting materials.
Jerrell Shelton, President, CEO, and Director of Cryoport (CYRX), executed significant stock option exercises and sales between June 17-20, 2025, as part of a pre-planned trading arrangement.
Key transactions include:
- Exercised options for 389,720 total shares at $5.00 strike price
- Sold 339,720 shares at weighted average prices between $6.33-$6.97
- Retained 50,000 shares from initial exercise
- Maintained beneficial ownership of 912,419 shares post-transactions
The transactions were conducted under a Rule 10b5-1 trading plan established on June 3, 2025. The exercised options were originally granted in August 2015 with a 48-month vesting schedule. After all transactions, Shelton continues to hold 166,344 unexercised stock options with an August 2025 expiration date.